WO2000050022A3 - Treatment regimen for hormone-sensitive cancers - Google Patents
Treatment regimen for hormone-sensitive cancers Download PDFInfo
- Publication number
- WO2000050022A3 WO2000050022A3 PCT/US2000/004879 US0004879W WO0050022A3 WO 2000050022 A3 WO2000050022 A3 WO 2000050022A3 US 0004879 W US0004879 W US 0004879W WO 0050022 A3 WO0050022 A3 WO 0050022A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone
- therapy
- treatment regimen
- estramustine
- months
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00914713A EP1154819A2 (en) | 1999-02-26 | 2000-02-25 | Treatment regimen for hormone-sensitive cancers |
AU36067/00A AU3606700A (en) | 1999-02-26 | 2000-02-25 | Treatment regimen for hormone-sensitive cancers |
CA002366697A CA2366697A1 (en) | 1999-02-26 | 2000-02-25 | Treatment regimen for hormone-sensitive cancers |
JP2000600634A JP2002537328A (en) | 1999-02-26 | 2000-02-25 | Treatment regimen for hormone-sensitive cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12209499P | 1999-02-26 | 1999-02-26 | |
US60/122,094 | 1999-02-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000050022A2 WO2000050022A2 (en) | 2000-08-31 |
WO2000050022A3 true WO2000050022A3 (en) | 2001-02-01 |
Family
ID=22400570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/004879 WO2000050022A2 (en) | 1999-02-26 | 2000-02-25 | Treatment regimen for hormone-sensitive cancers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1154819A2 (en) |
JP (1) | JP2002537328A (en) |
AU (1) | AU3606700A (en) |
CA (1) | CA2366697A1 (en) |
WO (1) | WO2000050022A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007067498A1 (en) * | 2005-12-06 | 2007-06-14 | Cell Therapeutics, Inc. | Estrogen cancer therapy |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
WO1994013277A2 (en) * | 1992-12-05 | 1994-06-23 | Imperial Cancer Research Technology Limited | Use of dinaphthalenes compounds as antiproliferative agents |
WO1997000683A1 (en) * | 1995-06-23 | 1997-01-09 | Georgetown University | Progesterone analogs to reverse multidrug resistance |
US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
WO1998014188A1 (en) * | 1996-10-04 | 1998-04-09 | Ilex Oncology, Inc. | Dfmo and taxol for the treatment or prevention of breast cancer |
WO1998025603A1 (en) * | 1996-12-13 | 1998-06-18 | Ilex Oncology, Inc. | Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer |
WO1998032440A1 (en) * | 1997-01-28 | 1998-07-30 | The Procter & Gamble Company | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
WO1998051303A1 (en) * | 1997-05-16 | 1998-11-19 | The Procter & Gamble Company | Hiv and cancer treatment |
FR2775187A1 (en) * | 1998-02-25 | 1999-08-27 | Novartis Ag | Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B |
-
2000
- 2000-02-25 CA CA002366697A patent/CA2366697A1/en not_active Abandoned
- 2000-02-25 WO PCT/US2000/004879 patent/WO2000050022A2/en not_active Application Discontinuation
- 2000-02-25 EP EP00914713A patent/EP1154819A2/en not_active Withdrawn
- 2000-02-25 AU AU36067/00A patent/AU3606700A/en not_active Abandoned
- 2000-02-25 JP JP2000600634A patent/JP2002537328A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775660A (en) * | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
US5676978A (en) * | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
WO1994013277A2 (en) * | 1992-12-05 | 1994-06-23 | Imperial Cancer Research Technology Limited | Use of dinaphthalenes compounds as antiproliferative agents |
WO1997000683A1 (en) * | 1995-06-23 | 1997-01-09 | Georgetown University | Progesterone analogs to reverse multidrug resistance |
WO1998014188A1 (en) * | 1996-10-04 | 1998-04-09 | Ilex Oncology, Inc. | Dfmo and taxol for the treatment or prevention of breast cancer |
WO1998025603A1 (en) * | 1996-12-13 | 1998-06-18 | Ilex Oncology, Inc. | Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer |
WO1998032440A1 (en) * | 1997-01-28 | 1998-07-30 | The Procter & Gamble Company | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
WO1998051303A1 (en) * | 1997-05-16 | 1998-11-19 | The Procter & Gamble Company | Hiv and cancer treatment |
FR2775187A1 (en) * | 1998-02-25 | 1999-08-27 | Novartis Ag | Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B |
Non-Patent Citations (5)
Title |
---|
ATIENZA, DANIEL M. ET AL: "Phase II study of oral etoposide for patients with advanced breast cancer", CANCER (PHILADELPHIA) (1995), 76(12), 2485-90, XP000957566 * |
BUZDAR ET AL: "Treatment of Advanced Breast Cancer with Aminoglutethimide after Therapy with Tamoxifen", CANCER, vol. 50, 1982, pages 1708 - 1712, XP000957573 * |
DAVIDSON, NEVILLE G.: "Single-agent paclitaxel as first-line treatment of metastatic breast cancer: The British experience", SEMIN. ONCOL. (1996), 23(5, SUPPL. 11), 6-10, XP000957565 * |
FURUYA, YUZO ET AL: "Apoptosis of androgen-independent mammary and prostate cell lines induced by topoisomerase inhibitors: common pathway of gene regulation", ANTICANCER RES. (1997), 17(3C), 2089-2093, XP000957553 * |
KOHLER, UWE ET AL: "Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study", SEMIN. ONCOL. (1997), 24(5, SUPPL. 17), 40-43, XP000957561 * |
Also Published As
Publication number | Publication date |
---|---|
AU3606700A (en) | 2000-09-14 |
WO2000050022A2 (en) | 2000-08-31 |
CA2366697A1 (en) | 2000-08-31 |
EP1154819A2 (en) | 2001-11-21 |
JP2002537328A (en) | 2002-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL244727A0 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
GEP20094798B (en) | (s,s)-reboxetine for treating chronic pain | |
MXPA03003960A (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders. | |
MXPA05012155A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases. | |
HK1046093A1 (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers. | |
MXPA03007837A (en) | Compositions for delivering bisphosphonates. | |
SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
HK1106736A1 (en) | Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers | |
HUP0203238A3 (en) | Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them | |
WO2005094899A8 (en) | Clusterin antisense therapy for treatment of cancer | |
WO2003106381A3 (en) | Human adam-10 inhibitors | |
WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
EP0934065A4 (en) | Pharmaceutical compounds | |
TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
EP1453812A4 (en) | Cytotoxic agents | |
EP1420827B8 (en) | 5-cnac as oral delivery agent for parathyroid hormone fragments | |
YU18099A (en) | Hormonal composition consisting of an oestrogen compound and of a progestational compound | |
GB0020504D0 (en) | Therapeutic method | |
HUP0302296A2 (en) | Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents | |
GB0129457D0 (en) | Method of treatment | |
MXPA02003484A (en) | Synergistic combinations of an nk1. | |
WO2000050022A3 (en) | Treatment regimen for hormone-sensitive cancers | |
EP0869786A4 (en) | Pharmaceutical compounds | |
WO2000050021A3 (en) | Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started | |
WO2001034174A3 (en) | Methods for administration of therapeutic agents on an antiangiogenic schedule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2366697 Country of ref document: CA Ref country code: CA Ref document number: 2366697 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 600634 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36067/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000914713 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000914713 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000914713 Country of ref document: EP |